Rockefeller Capital Management’s AbCellera Biologics ABCL Stock Holding History

Rockefeller Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.2K	Buy	9,577 +7,577	+379%	+$37K	﹤0.01%	3144
2026 Q1	$6.98K	Hold	2,000	–	–	﹤0.01%	4136
2025 Q4	$6.84K	Sell	2,000 -500	-20%	-$2.23K	﹤0.01%	3956
2025 Q3	$12.6K	Buy	+2,500	New	+$11K	﹤0.01%	3560
2023 Q1	–	Sell	-500	Closed	-$5K	–	1974
2022 Q4	$5K	Buy	+500	New	+$5.78K	﹤0.01%	3303
2022 Q3	–	Sell	-500	Closed	-$5K	–	3834
2022 Q2	$5K	Sell	500 -135	-21%	-$1.14K	﹤0.01%	3415
2022 Q1	$6K	Buy	635 +135	+27%	+$1.28K	﹤0.01%	3252
2021 Q4	$7K	Hold	500	–	–	﹤0.01%	3123
2021 Q3	$10K	Buy	+500	New	+$8.84K	﹤0.01%	2874

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Rockefeller Capital Management's ABCL Position: Q2 2026 in Review

Rockefeller Capital Management increased its AbCellera Biologics (ABCL) stake by 379% in Q2 2026, buying an estimated $37K and bringing the position to 9,577 shares worth $75.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3144.

Rockefeller Capital Management first reported a position in ABCL in Q3 2021 and has held it in 9 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Rockefeller Capital Management held 9,577 shares of AbCellera Biologics worth $75.2K as of Q2 2026.
Rockefeller Capital Management bought 7,577 AbCellera Biologics shares in Q2 2026, an estimated $37K.
AbCellera Biologics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3144 holding.
Rockefeller Capital Management first reported a position in AbCellera Biologics in Q3 2021 and has held it in 9 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.